Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight
The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.
New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight
The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.
Recently published Esophageal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, esophageal cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Esophageal Cancer Market Summary
- The market size for esophageal cancer was found to be USD 1.3 billion in the 7MM in 2025.
- The United States accounted for the largest esophageal cancer treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The total incident cases of esophageal cancer in the 7MM were approximately 79,000 in 2025.
- Key esophageal cancer companies, including Zymeworks, Jazz Pharmaceuticals, Amgen, AbbVie, Merck, Daiichi Sankyo, Eisai, Pfizer, Macrogenics, I-Mab, ABL Bio, and others, are actively working on innovative esophageal cancer drugs.
- Some of the key esophageal cancer therapies in clinical trials include Zanidatamab, Bemarituzumab, Telisotuzumab Adizutecan (Temab-A), Ifinatamab deruxtecan (MK-2400), Lenvatinib (LENVIMA), PF-08046033, MGC026, Ragistomig, and others. These novel esophageal cancer therapies are anticipated to enter the esophageal cancer market in the forecast period and are expected to change the market.
Discover esophageal cancer therapeutics market growth opportunities @ https://www.delveinsight.com/report-store/esophageal-cancer-market
Key Factors Driving the Growth of the Esophageal Cancer Market
- Rising Incidence of Esophageal Cancer: The increasing prevalence of esophageal cancer, particularly esophageal adenocarcinoma and squamous cell carcinoma, is a primary driver of market growth. Factors such as aging populations, obesity, gastroesophageal reflux disease (GERD), tobacco use, and alcohol consumption continue to contribute to the growing disease burden.
- Advancements in Multimodal Treatment Approaches: The current treatment approach for esophageal cancer typically combines surgery, chemotherapy, radiation therapy, and, more recently, immunotherapy. Advances in perioperative and neoadjuvant treatment strategies have contributed to improved patient survival, while individualized treatment plans based on tumor stage and histological subtype continue to enhance disease management and drive growth in the esophageal cancer market.
- Emergence of Immunotherapy and Targeted Therapies: The advent of immune checkpoint inhibitors, including Pembrolizumab (KEYTRUDA), Nivolumab (OPDIVO), Tislelizumab (TEVIMBRA), and Durvalumab (IMFINZI), has reshaped the treatment paradigm for advanced and metastatic disease by delivering meaningful improvements in patient survival. At the same time, targeted therapies such as Ramucirumab (CYRAMZA) and Larotrectinib (VITRAKVI) are broadening therapeutic opportunities for patients with specific biomarker-defined profiles.
- Growing Focus on Precision Medicine and Biomarker-Driven Therapies: Recent progress in molecular diagnostics has improved the detection of actionable genetic alterations, supporting the advancement of targeted treatment strategies. Biomarker-guided therapies, such as those directed at HER2 and NTRK, are playing an increasingly important role in treatment selection, enhancing clinical outcomes and accelerating the adoption of personalized medicine for esophageal cancer.
- Robust Pipeline of Novel Therapeutics: A strong pipeline of investigational drugs, including Zanidatamab (Zymeworks/Jazz Pharmaceuticals), Bemarituzumab (Amgen), Telisotuzumab Adizutecan (Temab-A) (AbbVie), Ifinatamab deruxtecan (MK-2400) (Merck/Daiichi Sankyo), Lenvatinib (LENVIMA) (Merck/Eisai), PF-08046033 (Pfizer), MGC026 (Macrogenics), Ragistomig (I-Mab/ABL Bio), and others is expected to reshape the treatment landscape. Continuous clinical development is attracting investments and expanding future market potential.
Aparna Thakur, project manager of forecasting at DelveInsight, said that the emerging therapies, including HER2-targeted agents such as Zanidatamab, FGFR2b-targeted therapies such as Bemarituzumab, and antibody-drug conjugates like Telisotuzumab adizutecan (Temab-A), are expected to witness gradual but steady uptake over the forecast period. Their adoption will largely depend on clinical trial outcomes, regulatory approvals, and the expansion of biomarker testing to identify eligible patient populations.
Esophageal Cancer Market Analysis
- Systemic therapy plays a central role in the management of esophageal cancer by delivering medications through the bloodstream to target cancer cells throughout the body. The major systemic treatment approaches include chemotherapy, targeted therapies, and immunotherapies.
- Among targeted therapies, trastuzumab (HERCEPTIN/OGIVRI) is used in combination with chemotherapy as a first-line treatment for patients with metastatic esophageal adenocarcinoma.
- Trastuzumab deruxtecan (ENHERTU) is also approved for first-line treatment in this setting. For patients with advanced gastroesophageal or gastroesophageal junction adenocarcinoma whose disease has progressed following initial therapy, ramucirumab (CYRAMZA) combined with paclitaxel represents an established treatment option.
- Immunotherapy has significantly broadened the therapeutic landscape of esophageal cancer. PD-1/PD-L1 checkpoint inhibitors such as pembrolizumab (KEYTRUDA) and nivolumab (OPDIVO) have gained regulatory approval, while additional immune-targeted agents, including ipilimumab (YERVOY), tislelizumab-jsgr (TEVIMBRA), and zolbetuximab-clzb (VYLOY), further expand the available treatment arsenal.
- The esophageal cancer pipeline continues to evolve, with several promising candidates under clinical development. Notable investigational therapies include Zanidatamab (Zymeworks/Jazz Pharmaceuticals), Bemarituzumab (Amgen), Telisotuzumab Adizutecan (Temab-A) (AbbVie), Ifinatamab deruxtecan (MK-2400) (Merck/Daiichi Sankyo), Lenvatinib (LENVIMA) (Merck/Eisai), PF-08046033 (Pfizer), MGC026 (Macrogenics), Ragistomig (I-Mab/ABL Bio), and others, alongside several other emerging therapies that have the potential to reshape future treatment paradigms.
Learn more about disease-modifying therapies for esophageal cancer @ Esophageal Cancer Treatment Market
Esophageal Cancer Competitive Landscape
Some of the esophageal cancer drugs under development include Zanidatamab (Zymeworks/Jazz Pharmaceuticals), Bemarituzumab (Amgen), Telisotuzumab Adizutecan (Temab-A) (AbbVie), Ifinatamab deruxtecan (MK-2400) (Merck/Daiichi Sankyo), Lenvatinib (LENVIMA) (Merck/Eisai), PF-08046033 (Pfizer), MGC026 (Macrogenics), Ragistomig (I-Mab/ABL Bio), and others.
Zymeworks/Jazz Pharmaceuticals’ Zanidatamab is an advanced-stage investigational oncology therapy designed to target multiple HER2-expressing malignancies and has the potential to redefine treatment approaches across several cancer indications. The therapy has shown encouraging clinical efficacy in biliary tract cancer and gastroesophageal adenocarcinoma (GEA), with broader applicability anticipated in additional HER2-positive tumors. It has also been granted Fast Track Designation (FTD) for use in combination with standard chemotherapy as a first-line treatment for gastroesophageal adenocarcinoma. The ongoing Phase III HERIZON-GEA-01 study is assessing zanidatamab alongside chemotherapy, with or without the PD-1 inhibitor tislelizumab, as an initial treatment option for patients with metastatic HER2-positive GEA.
Merck/Eisai’s Lenvatinib is an oral multi-targeted kinase inhibitor that blocks signaling through vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), thereby suppressing tumor angiogenesis. In addition to VEGF receptors, it inhibits several other kinases involved in cancer development and progression, including fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. The therapy is being co-developed with KEYTRUDA, and the combination is currently under evaluation in a Phase III clinical trial for metastatic esophageal carcinoma. Development of LENVIMA is being carried out through a collaboration with Eisai.
AbbVie’s Telisotuzumab adizutecan is an investigational antibody-drug conjugate (ADC) that targets c-Met, a receptor commonly overexpressed in various solid malignancies. The therapy is currently being investigated across multiple tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastroesophageal adenocarcinoma.
Merck/Daiichi Sankyo’s Ifinatamab deruxtecan is a novel investigational antibody-drug conjugate composed of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. The candidate is being jointly developed through a collaboration with Daiichi Sankyo.
The anticipated launch of these emerging esophageal cancer therapies are poised to transform the esophageal cancer market landscape in the coming years. As these cutting-edge esophageal cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the esophageal cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about emerging esophageal cancer therapies, visit @ Esophageal Cancer Medication
Recent Developments in the Esophageal Cancer Market
- In November 2025, the FDA approved durvalumab (IMFINZI, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
- In November 2025, Pembrolizumab (KEYTRUDA) in combination with chemotherapy showed sustained long-term survival benefit in advanced esophageal cancer, with 5-year follow-up data from the Phase III KEYNOTE-590 study confirming improved overall survival and progression-free survival versus chemotherapy alone.
- In March 2025, Tislelizumab (TEVIMBRA) received FDA approval in combination with chemotherapy for first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) with PD-L1 expression, marking an important addition to frontline immunotherapy options.
Esophageal Cancer Epidemiology Segmentation
The esophageal cancer epidemiology section provides insights into the historical and current esophageal cancer patient pool and forecasted trends for the leading markets. It has been observed that the incidence of non-squamous cell esophageal cancer is higher (~14,000) as compared to squamous cell esophageal cancer (~8,000) in the United States.
The esophageal cancer market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Total Diagnosed Incident Cases of Esophageal Cancer
- Histology-specific Cases of Esophageal Cancer
- Gender-specific Cases of Esophageal Cancer
- Age-specific Cases of Esophageal Cancer
- Mutation-specific Cases of Esophageal Cancer
- Total Stage-specific Cases of Esophageal Cancer
- Line wise Treated Cases of Esophageal Cancer
Download the report to understand the future of esophageal cancer treatment @ Esophageal Cancer Treatment Options
| Esophageal Cancer Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Esophageal Cancer Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Esophageal Cancer Market CAGR | 6% |
| Esophageal Cancer Market Size in 2025 | USD 1.3 Billion |
| Key Esophageal Cancer Companies | Zymeworks, Jazz Pharmaceuticals, Amgen, AbbVie, Merck, Daiichi Sankyo, Eisai, Pfizer, Macrogenics, I-Mab, ABL Bio, BeiGene, AstraZeneca, and others |
| Key Esophageal Cancer Therapies | Zanidatamab, Bemarituzumab, Telisotuzumab Adizutecan (Temab-A), Ifinatamab deruxtecan (MK-2400), Lenvatinib (LENVIMA), PF-08046033, MGC026, Ragistomig, TEVIMBRA, IMFINZI, and others |
Scope of the Esophageal Cancer Market Report
- Esophageal Cancer Patient Population Forecast
- Esophageal Cancer Therapeutics Market Size
- Esophageal Cancer Pipeline Analysis
- Esophageal Cancer Market Size and Trends
- Esophageal Cancer Market Opportunity
- Esophageal Cancer Market Unmet Needs
- KOL’s Views on Esophageal Cancer
- Esophageal Cancer Market Access and Reimbursement
Discover more about next-generation esophageal cancer drugs @ Esophageal Cancer Clinical Trials
Table of Contents
| 1 | Esophageal Cancer Market Key Insights |
| 2 | Esophageal Cancer Market Report Introduction |
| 3 | Executive Summary |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | Esophageal Cancer Market Overview at a Glance |
| 6.1 | Clinical Landscape Analysis (By Phase, Molecule Type, and RoA) |
| 6.2 | Market Share (%) Distribution of Esophageal Cancer By Therapies in the 7MM, in 2025 |
| 6.3 | Market Share (%) Distribution of Esophageal Cancer By Therapies in the 7MM, in 2036 |
| 7 | Disease Background and Overview of Esophageal Cancer |
| 7.1 | Introduction |
| 7.2 | Types |
| 7.3 | Symptoms |
| 7.4 | Causes |
| 7.5 | Pathophysiology |
| 7.6 | Diagnosis |
| 7.7 | Treatment |
| 8 | Treatment Guidelines of Esophageal Cancer |
| 9 | Epidemiology and Patient Population of Esophageal Cancer |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Total Incident Cases of Esophageal Cancer in the 7MM |
| 9.4 | The United States |
| 9.4.1 | Total Diagnosed Incident Cases of Esophageal Cancer in the United States |
| 9.4.2 | Histology-specific Cases of Esophageal Cancer in the United States |
| 9.4.3 | Gender-specific Cases of Esophageal Cancer in the United States |
| 9.4.4 | Age-specific Cases of Esophageal Cancer in the United States |
| 9.4.5 | Mutation-specific Cases of Esophageal Cancer in the United States |
| 9.4.6 | Total Stage-specific Cases of Esophageal Cancer in the United States |
| 9.4.7 | Line-wise Treated Cases of Esophageal Cancer in the United States |
| 9.5 | EU4 and the UK |
| 9.6 | Japan |
| 10 | Patient Journey of Esophageal Cancer |
| 11 | Marketed Esophageal Cancer Therapies |
| 11.1 | Marketed Competitive Landscape of Esophageal Cancer |
| 11.2 | Entrectinib (ROZLYTREK): Eli Lilly and Company |
| 11.2.1 | Drug Description |
| 11.2.2 | Regulatory Milestones |
| 11.2.3 | Other Developmental Activities |
| 11.2.4 | Summary of Pivotal Trials |
| 11.2.5 | Clinical Development |
| 11.2.5.1 | Clinical Trial Information |
| 11.2.6 | Analyst Views |
| 11.3 | Entrectinib (ROZLYTREK): Eli Lilly and Company |
| 11.4 | Tislelizumab (TEVIMBRA): BeiGene |
| List to be continued in the report… | |
| 12 | Emerging Esophageal Cancer Drugs |
| 12.1 | Emerging Competitive Landscape of Esophageal Cancer |
| 12.2 | Zanidatamab: Jazz Pharmaceuticals/Zymeworks |
| 12.2.1 | Drug Description |
| 12.2.2 | Other Developmental Activity |
| 12.2.3 | Clinical Development |
| 12.2.3.1 | Clinical Trials Information |
| 12.2.4 | Analyst Views |
| 12.3 | Telisotuzumab adizutecan: AbbVie |
| List to be continued in the report… | |
| 13 | Esophageal Cancer Market: 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Market Outlook of Esophageal Cancer |
| 13.3 | Key Market Forecast Assumptions |
| 13.4 | Conjoint Analysis of Esophageal Cancer |
| 13.5 | Total Market Size of Esophageal Cancer in the 7MM |
| 13.6 | Total Market Size of Esophageal Cancer by Therapies in the 7MM |
| 13.7 | The United States Esophageal Cancer Market |
| 13.7.1 | Total Market Size of Esophageal Cancer in the United States |
| 13.7.2 | Total Market Size of Esophageal Cancer by Therapies in the United States |
| 13.8 | EU4 and the UK Esophageal Cancer Market |
| 13.9 | Japan Esophageal Cancer Market |
| 14 | Unmet Needs of Esophageal Cancer |
| 15 | SWOT Analysis of Esophageal Cancer |
| 16 | KOL Views of Esophageal Cancer |
| 17 | Market Access and Reimbursement of Esophageal Cancer |
| 17.1 | The United States |
| 17.2 | EU4 and the UK |
| 17.3 | Japan |
| 17.4 | Summary and comparison of Market Access and Pricing Policy Developments in 2025 |
| 17.5 | Market Access and Reimbursement of Esophageal Cancer Therapies |
| 18 | Bibliography |
| 19 | Esophageal Cancer Market Report Methodology |
Related Reports
Esophageal Cancer Clinical Trial Analysis
Esophageal Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal cancer companies, including OncoTherapy Science, Inc., Shionogi & Co., Oncolys BioPharma Inc., Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech, NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics, and others.
Gastroesophageal Reflux Disease Market
Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key GERD companies including Phathom Pharmaceuticals, Inc., Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca, and others.
Gastroesophageal Reflux Disease Clinical Trial Analysis
Gastroesophageal Reflux Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, and others.
Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HNC companies, including CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, and others.
Head and Neck Cancer Clinical Trial Analysis
Head and Neck Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HNC companies, including Merus, Bicara Therapeutics, Kura Oncology, Inc., Theriva Biologics, Nykode Therapeutics ASA, Cue Biopharma, BioNTech SE, Exelixis, AstraZeneca, Johnson & Johnson, Intragel, AbbVie, IOVANCE Biotherapeutics, Immutep Limited, Repertoire Immune Medicines, Pyxis Oncology, Inc., ALX Oncology, iTeos Therapeutics, AVEO Oncology, Akeso Biopharma, Coherus BioSciences, Inc., Flamingo Therapeutics, Adlai Nortye Ltd, Hibercell Inc., Elpiscience Biopharmaceuticals, KSQ Therapeutics, Transgene, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
